CVS / CVS Health launches biosimilars subsidiary, will commercialize Humira competitor

CVS Health stock dipped after the company reported third-quarter results on Nov. 1. CVS Health's largest operating segment lost a big client earlier t more_horizontal

The list of over-the-counter eye drops that the Food and Drug Administration warns could lead to serious infections continues to grow, with the federa more_horizontal

CVS Health Corp and Walgreens Boots Alliance on Wednesday said that a work action by some U.S. pharmacists this week had minimal impact on operations, more_horizontal

CVS Health delivered better-than-expected revenue and earnings for its third quarter of 2023. The pharmacy chain also lowered its full-year earnings o more_horizontal

Robust sales growth across all three operating segments drove CVS Health's (CVS) third-quarter results. more_horizontal

CVS Health (CVS) posted better-than-expected results on gains in its health services business, but shares fell 1% in early trading Wednesday as the bi more_horizontal

CVS Health Corp (NYSE:CVS) bobbed and weaved to put the best gloss on its third-quarter earnings update early on – only to see the stock flop 4.2% p more_horizontal

CVS Health reported third quarter net income of $2.2 billion thanks in part to contributions from its new healthcare services acquisitions. more_horizontal